AnaptysBio Q2 FY26 net income from continuing operations more than doubles to $177.3 million; revenue rises 23.5% to $27.49 million
ANAB•Q2 results
AnaptysBio posted Q2 net income from continuing operations of $177.3 million, versus $5.7 million a year earlier.
Q2 collaboration revenue rose 23.47% year over year to $27.49 million, while general and administrative expenses climbed to $16.04 million.
Jemperli and Quimilza updates
Management flagged Jemperli global net sales of $644 million for the six months ended June 30, up 34% year over year.
Updates include a Feb. 2027 FDA PDUFA date for Jemperli in rectal cancer and a Dec. 12, 2026 PDUFA date for Quimilza in GPP.
Cash position and operating details
Cash, cash equivalents and investments totaled $164.1 million at June 30, down from $211.6 million at Dec. 31, 2025.
Related News
Sun Life converts variable-rate preferred shares into fixed-rate issue, leaving none outstanding
SLF•
Optimum Communications flags prior financial statements as unreliable, plans restatement over deferred tax errors
OPTU•
